Control of allergic airway inflammation through immunomodulation

David Corry, Farrah Kheradmand

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Among the asthma clinical trials published over the last several years, a unique subset has focused on novel means for inhibiting the airway inflammation that is believed to cause airway obstruction in many patients. Such interventions, broadly considered here as immune-modifying or immunomodulatory therapies, include several new drugs (omalizumab, suplatast tosilate, anti-cytokine antibodies, soluble receptors, and recombinant cytokines) and bacterial extracts. In this chapter we review the major findings with these clinical trials and indicate which have changed the management of asthma, which have not, and those that deserve further study.

Original languageEnglish (US)
Pages (from-to)S461-S464+S487
JournalJournal of Allergy and Clinical Immunology
Issue number2 SUPPL. 2
StatePublished - Feb 2006


  • Airway hyperreactivity
  • Asthma
  • Eosinophil
  • IgE
  • Immunomodulation
  • Immunostimulatory sequence
  • Interleukin
  • Mast cell
  • T2 cell
  • Type I hypersensitivity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Control of allergic airway inflammation through immunomodulation'. Together they form a unique fingerprint.

Cite this